Detail

G17DT

Description

Name: G17DT
Type: biotech
Groups: investigational
Indication: Intended for the treatment of various forms of cancer.
Accession Number: DB04914 ( DB04914)
Description: G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients

Categories
  • Antineoplastic Agents
  • Vaccines

Pharmacology

Indication: Intended for the treatment of various forms of cancer.
Pharmacodynamics: Not Available
Mechanism of action: When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a stomach and pancreatic cancer growth factor.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
  • Not Available

Dosage forms
FormRouteStrength

Prices
Unit descriptionCostUnit

Patents
CountryPatent NumberApprovedExpires (estimated)

Interactions

Drug Interactions
DrugInteraction

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Not Available

substituent:
  • Not Available

References

Synthesis Reference: Not Available
General Reference: # Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT. BioDrugs. 2003;17(3):223-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12749761 # Gilliam AD, Watson SA: G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17309331 # Ajani JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1;106(9):1908-16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16568451 # He AR, Marshall JL: Clinical experiences with G17DT in gastrointestinal malignancies. Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16613537 # Watson SA, Gilliam AD: G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther. 2001 Mar;1(2):309-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11727538 # Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002 Oct 15;20(20):4225-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12377966 # Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 2004 Jun;30(5):536-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15135483 # Takhar AS, Gilliam AD, Watson SA, Henwood M, Rowlands BJ, Broome P, Beckingham IJ: The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur J Surg Oncol. 2006 Mar;32(2):197-200. Epub 2005 Oct 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16246519
External Links:
ResourceLink

ATC Codes:
  • Not Available

AHFS Codes:
  • Not Available

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?